Search clinical trials for: Vaccine FP-01.1

Total 7031 results

Immune Targeting Systems Ltd

Completed

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

Influenza A
Immune Targeting Systems Ltd
INCResearch Australia Pty Limited

Completed

Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)

Influenza A

Australia
Immune Targeting Systems Ltd

Completed

Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge

Influenza A

United Kingdom
Immune Targeting Systems Ltd
Hammersmith Medicines Research

Completed

A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine

Influenza

United Kingdom
Vaxart

Completed

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

Norovirus Gastroenteritis

United States
Vaxart

Completed

Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults

Seasonal Influenza Preventative Vaccine Pharmacodynamics

United States
National Institute of Allergy and Infectious Diseases...
National Institutes of Health (NIH); Department of Health and Human Services

Suspended

A Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine Alone or in Prime-Boost Regimens With Adjuvanted HIV-1 Envelope Trimer 4571 and HIV-1 Trimer 6931 Vaccines in Healthy Adults

HIV

United States
FHI 360
Ministry of Health, Uganda

Completed

Community-based Delivery of Integrated Family Planning/HIV Testing and Counseling Services in Uganda

HIV Testing and Counseling

Uganda
Altimmune, Inc.

Completed

Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B

Hepatitis B

Korea, Republic of, United Kingdom
Vaxart

Completed

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

Norovirus Gastroenteritis

United States
Foresee Pharmaceuticals Co., Ltd.

Completed

The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses and Airway Inflammation in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma

Asthma, COPD

Netherlands
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Japan, Israel, Austria, Bulgaria, France, Germany, Italy, Russian Federation, Spain
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of California, San Francisco
Population Services International

Completed

Improving Person-Centered Care for Family Planning in India (SPARQ_FPI)

Family Planning

India
Fervent Pharmaceuticals
ICON plc

Completed

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Vasomotor Symptoms | Menopause

United States
Five Prime Therapeutics, Inc.
Parexel

Completed

Safety Study of FP-1039 To Treat Cancer

Advanced Cancer

United States
CSL Behring

Completed

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Hemophilia B

Germany, Australia, Italy, Israel, Czech Republic, Spain, France, Canada, Austria, Russian Federation
ANRS, Emerging Infectious Diseases
LinKinVax; Vaccine Research Institute (VRI), France

Not yet recruiting

Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.

COVID-19
Foresee Pharmaceuticals Co., Ltd.

Recruiting

A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia

Fanconi Anemia

United States
CSL Behring

Completed

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Hemophilia B

United States, Australia, Japan, France, Philippines, Spain, Czechia, Israel, Canada, Germany, Austria, Bulgaria, Italy, Malaysia, South Africa
Five Prime Therapeutics, Inc.
Worldwide Clinical Trials

Withdrawn

Study of FP-1039 in Subjects With Endometrial Cancers

Endometrial Cancers With FGFR2 Mutations
National Cancer Institute (NCI)

Completed

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

Neoplasms | Breast Cancer | Lung Cancer | Prostate Cancer | Colon Cancer

United States
National Institute of Allergy and Infectious Diseases...

Completed

ACAM 3000 MVA at Harvard Medical School

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

Combination Study With MVA BN and Dryvax

Smallpox

United States
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (The PEARL Study)

Dry Eye Disease

United States
University of Oxford

Completed

The Safety and Immunogenicity of a TB Vaccine; MVA85A, in Healthy Volunteers Who Are Infected With HIV

HIV Infections | Tuberculosis

United Kingdom
Foresee Pharmaceuticals Co., Ltd.

Terminated

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Severe to Critical COVID 19 With Associated ARDS

United States
Foresee Pharmaceuticals Co., Ltd.

Completed

Multiple-Dose, Dose-Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of FP-045

Healthy Volunteers

Australia
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
Vaxart

Completed

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers ((VXA-G1-1-NN))

Norovirus Infections

United States
Foresee Pharmaceuticals Co., Ltd.
InClin, Inc.

Not yet recruiting

Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Ascending Doses of FP-020 in Healthy Adult Volunteers

Healthy

Australia
National University Health System, Singapore

Active, not recruiting

Artificial Intelligence in Categorizing the Severity of Oxygenation by Incorporating the PEEP Into the Definition of ARDS in Ventilated Patients (P/FP ratio)

ARDS

Singapore
Foresee Pharmaceuticals Co., Ltd.
QPS-Qualitix

Completed

Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers

Healthy

Taiwan
National University Health System, Singapore

Completed

PaO2/FiO2*PEEP (P/FP) Ratio and Mortality in Acute Respiratory Distress Syndrome.

Adult Respiratory Distress Syndrome

Singapore
GlaxoSmithKline

Completed

A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics

Asthma

Germany
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer

Prostate Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
Foresee Pharmaceuticals Co., Ltd.

Completed

A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

Healthy

Netherlands
Fervent Pharmaceuticals
Iqvia Pty Ltd

Completed

FP-101 for the Treatment of Hot Flashes in Postmenopausal Women

Hot Flashes

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
BeBetter Med Inc
Xiangya Hospital of Central South University

Recruiting

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Advanced or Metastatic Solid Tumor | KRAS G12C Mutation

China
Southwest Oncology Group
National Cancer Institute (NCI)

Withdrawn

S0348 Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission

Breast Cancer
Ivan Litvinov

Terminated

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer (MUSIC-01)

Basal Cell Carcinoma | Squamous Cell Carcinoma | Non-melanoma Skin Cancer

Canada
Medical University of South Carolina

Completed

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

Aging | HIV Lipodystrophy

United States
Leena Nahata
National Cancer Institute (NCI)

Enrolling by invitation

Fertility Preservation in Male AYA With Cancer

Infertility, Male

United States
Texas Tech University
Alliance for Potato Research and Education

Active, not recruiting

Effects of Potatoes on Blood Pressure in Persons With and Without Type 2 Diabetes Who Follow the DASH Diet for 6 Weeks

Type 2 Diabetes | Blood Pressure

United States
Emergent BioSolutions

Completed

Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults

Smallpox

United States
GlaxoSmithKline

Completed

GSK BHR Study (Sont - Second Study)

Asthma

United States, Bulgaria, Puerto Rico, Brazil
Vaxart

Completed

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines (VXA-NVV-103)

Norovirus Infection

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus

Cytomegalovirus Infection | Healthy, no Evidence of Disease

United States

Search clinical trials for: Vaccine FP-01.1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations